- Home
- RLTY vs GNLX Comparison
RLTY vs GNLX Comparison
Compare RLTY & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$2.44
Company Overview
Basic Information| Metric | RLTY | GNLX |
|---|---|---|
| Founded | 2022 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.8M | 202.4M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | RLTY | GNLX |
|---|---|---|
| Price | $15.16 | $2.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.75 |
| AVG Volume (30 Days) | 86.7K | ★ 292.1K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 9.35% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.38 | $1.99 |
| 52 Week High | $14.60 | $8.54 |
Technical Indicators
Market Signals| Indicator | RLTY | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 60.58 | 26.61 |
| Support Level | $14.84 | $2.32 |
| Resistance Level | $15.14 | $2.97 |
| Average True Range (ATR) | 0.18 | 0.17 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 95.24 | 4.00 |
Price Performance
Historical Comparison RLTY
GNLX
About RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is an organized, non-diversified, closed-end management investment company. The Fund's primary investment objective is high current income. The Fund's secondary investment objective is capital appreciation.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.